EGFR and non-small cell lung carcinoma: The discovery of epidermal growth factor receptor (EGFR) mutation [1,2] and the introduction of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized the treatment strategy for non-small-cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations [3].